David B. Chapel YOU? Author Swipe

Last 10y

Immunohistochemical characterization of peritoneal inclusion cysts with squamous metaplasia Open

Heather Chen, David B. Chapel, Steven Hrycaj, William Perry, Kristine E. Konopka , et al. · 2025

Aims Peritoneal inclusion cysts (PICs) are mesothelial‐lined cysts that can uncommonly develop squamous metaplasia. Here, we describe the immunophenotype of PICs with squamous metaplasia using a comprehensive immunohistochemical (IHC) pane…

The Anatomic Pathology Hospitalist Model : A Novel Approach to Frozen Section Practice in a Tertiary Care Center Open

Ellen E. Chapel, David B. Chapel, Lakshimi P. Kunju, John A. Hamilton, Jeffrey L. Myers , et al. · 2024

Context.— Challenges to staffing a high-quality frozen section service include consolidation of health systems and pathology practices, off-campus relocation of some pathology offices, growing numbers of stand-alone surgery centers, and su…

Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest Group Open

Aliya N. Husain, David B. Chapel, Richard Attanoos, Mary Beth Beasley, Luka Brčić , et al. · 2024

Context.— Mesothelioma is an uncommon tumor that can be difficult to diagnose. Objective.— To provide updated, practical guidelines for the pathologic diagnosis of mesothelioma. Data Sources.— Pathologists involved in the International Mes…

Figure S4 from Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer Open

Melissa Javellana, Mark A. Eckert, Janna Heide, Katarzyna Zawieracz, Melanie Weigert , et al. · 2023

Supplementary Figure 4

Figure S4 from Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer Open

Melissa Javellana, Mark A. Eckert, Janna Heide, Katarzyna Zawieracz, Melanie Weigert , et al. · 2023

Supplementary Figure 4

Data from Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer Open

Melissa Javellana, Mark A. Eckert, Janna Heide, Katarzyna Zawieracz, Melanie Weigert , et al. · 2023

The growing use of neoadjuvant chemotherapy to treat advanced stage high-grade serous ovarian cancer (HGSOC) creates an opportunity to better understand chemotherapy-induced mutational and gene expression changes. Here we performed a cohor…

Figure S2 from Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer Open

Melissa Javellana, Mark A. Eckert, Janna Heide, Katarzyna Zawieracz, Melanie Weigert , et al. · 2023

Supplementary Figure 2

Supplementary Tables S1-14 from Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer Open

Melissa Javellana, Mark A. Eckert, Janna Heide, Katarzyna Zawieracz, Melanie Weigert , et al. · 2023

Supplementary Tables

Figure S2 from Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer Open

Melissa Javellana, Mark A. Eckert, Janna Heide, Katarzyna Zawieracz, Melanie Weigert , et al. · 2023

Supplementary Figure 2

Supplementary Table and Figure Legends from Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer Open

Melissa Javellana, Mark A. Eckert, Janna Heide, Katarzyna Zawieracz, Melanie Weigert , et al. · 2023

Supplementary Table and Figure Legends

Figure S1 from Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer Open

Melissa Javellana, Mark A. Eckert, Janna Heide, Katarzyna Zawieracz, Melanie Weigert , et al. · 2023

Supplementary Figure 1

Supplementary Table and Figure Legends from Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer Open

Melissa Javellana, Mark A. Eckert, Janna Heide, Katarzyna Zawieracz, Melanie Weigert , et al. · 2023

Supplementary Table and Figure Legends

Data from Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer Open

Melissa Javellana, Mark A. Eckert, Janna Heide, Katarzyna Zawieracz, Melanie Weigert , et al. · 2023

The growing use of neoadjuvant chemotherapy to treat advanced stage high-grade serous ovarian cancer (HGSOC) creates an opportunity to better understand chemotherapy-induced mutational and gene expression changes. Here we performed a cohor…

Figure S1 from Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer Open

Melissa Javellana, Mark A. Eckert, Janna Heide, Katarzyna Zawieracz, Melanie Weigert , et al. · 2023

Supplementary Figure 1

Supplementary Tables S1-14 from Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer Open

Melissa Javellana, Mark A. Eckert, Janna Heide, Katarzyna Zawieracz, Melanie Weigert , et al. · 2023

Supplementary Tables

Figure S3 from Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer Open

Melissa Javellana, Mark A. Eckert, Janna Heide, Katarzyna Zawieracz, Melanie Weigert , et al. · 2023

Supplementary Figure 3

Figure S3 from Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer Open

Melissa Javellana, Mark A. Eckert, Janna Heide, Katarzyna Zawieracz, Melanie Weigert , et al. · 2023

Supplementary Figure 3

Dedifferentiated leiomyosarcoma of the uterus: a clinicopathologic and immunohistochemical analysis of 23 cases Open

David B. Chapel, Livia Macciò, Emma Bragantini, Gian Franco Zannoni, Bradley J. Quade , et al. · 2023

Aims To morphologically and immunophenotypically characterize dedifferentiated uterine leiomyosarcoma (LMS). Methods and results We identified 23 dedifferentiated uterine LMS, defined as a malignant uterine smooth muscle tumour containing …

Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma Open

David B. Chapel, Jason L. Hornick, Julianne Barlow, Raphael Bueno, Lynette M. Sholl · 2022

Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention Open

Ju‐Yoon Yoon, David B. Chapel, Emily A. Goebel, Xiaohua Qian, Jeffrey K. Mito , et al. · 2022

The current theory of carcinogenesis for the deadliest of ‘ovarian’ cancers—high‐grade serous carcinoma (HGSC)—holds that the malignancy develops first in the fallopian tube and spreads to the ovaries, peritoneum, and/or regional lymph nod…

A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: an analysis of 203 cases Open

David B. Chapel, Aarti Sharma, Ricardo R. Lastra, Livia Macciò, Emma Bragantini , et al. · 2022

Next-Generation Sequencing in the Diagnosis of Metastatic Lesions: Reclassification of a Glioblastoma as an Endometrial Cancer Metastasis to the Brain Open

Shuk On Annie Leung, Olivia Foley, David B. Chapel, Annacarolina da Silva, Marisa R. Nucci , et al. · 2021

Endometrial cancer is the most common gynecologic cancer in the U.S., but metastasis to the brain is rare, and diagnosis can be challenging. Traditional tools for determining if a tumor is a primary or metastatic lesion include pan-imaging…

Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases Open

David B. Chapel, Jefree J. Schulte, Gudrun Absenger, Richard Attanoos, Luka Brčić , et al. · 2020

Pro-lymphangiogenic VEGFR-3 signaling modulates memory T cell responses in allergic airway inflammation Open

Katharina Maisel, Cara L. Hrusch, Jorge Emiliano Gomez Medellin, Lambert Potin, David B. Chapel , et al. · 2020

Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center Open

Françoise Galateau-Sallé, Nolwenn Le Stang, Franck Tirode, Pierre Courtiol, Andrew G. Nicholson , et al. · 2020

Application of immunohistochemistry in diagnosis and management of malignant mesothelioma Open

David B. Chapel, Jefree J. Schulte, Aliya N. Husain, Thomas Krausz · 2020

Immunohistochemistry plays an indispensable role in accurate diagnosis of malignant mesothelioma, particularly in morphologically challenging cases and in biopsy and cytology specimens, where tumor architecture is difficult or impossible t…

Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas Open

Sanja Đačić, Nolwenn Le Stang, Aliya N. Husain, Birgit Weynand, Mary Beth Beasley , et al. · 2019

MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma Open

David B. Chapel, Jefree J. Schulte, Kyra B. Berg, Andrew Churg, Sanja Đačić , et al. · 2019

Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma Open

David B. Chapel, Sushant Patil, Andrei Plagov, Rutika Puranik, Anastasiya Mendybaeva , et al. · 2019

Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays Open

David B. Chapel, Rachel L. Stewart, Larissa V. Furtado, Aliya N. Husain, Thomas Krausz , et al. · 2019

Malignant mesothelioma (MM) is an aggressive neoplasm with poor prognosis. The Dako PD-L1 22C3 and 28-8 pharmDx assays are approved by the US Food and Drug Administration (FDA) as companion and complementary diagnostics for the anti-PD-1 d…

Fetching topic information...